Xenoport, Inc.

Arbor Pharmaceuticals, LLC

Xwpharma Ltd.

Alexion Pharmaceuticals, Inc.

Rapt Therapeutics, Inc.

Arixa Pharmaceuticals, Inc.

Sami Karaborni

Chen Mao

Daniel M Canafax

William W Xiang

Suresh Kumar Manthati

Wei Chen

Jia-Ning Xiang

David Juergen Wustrow

Peter Virsik

Randall A Scheuerman

Jia-ning Xiang

Ching Wah Chong

Annette Grave

James Tien

Sarina Grace Harris Ma

Mesut Ciper

Stefanie Thiel

Norbert Pollinger

Stefanie Krenzlin

Peter Robert Prinz Freed

Anjali Pandey

Venkat R Thalladi

Julian Scott Northen

Philippe Fernandes

Ying Chen

Manshiu Leung

Nicolas D Kirkland

Yuelie Lu

Gus Kodersha

Kenneth C Cundy

Mikhail Zibinsky

Scott Lawrence Childs

Omar Robles

Duane E Rudisill

David J Arnold

Peter A Virsik

Sarina Grace Ma

Peter Robert Freed

Nikhil Pargaonkar

David J Kidney

David E Edgren

Derrick K Kim

Gorm Yoder

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Pharmaceutical compositions of dimethyl fumarate

Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Modified release compositions of a gamma-hydroxybutyric acid derivative

Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.

Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Controlled release granulations of water-soluble active pharmaceutical ingredients

Crystalline forms of a C-C chemokine receptor type 4 (CCR4) antagonist, oral dosage forms of same and methods of using and preparing same, are provided.

Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof

Modified release compositions of a GAMMA-hydroxybutyric acid derivative

Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.

Solid forms of Cerdulatinib

Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface.

Pharmaceutical granulations of water-soluble active pharmaceutical ingredients

Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.

Pharmaceutical compositions of fumaric acid esters

A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.

Crystalline form of an avibactam derivative

Growing community of inventors

Cupertino, CA, United States of America

Sami Karaborni